Our Lead Product Candidate:
Obeticholic Acid (OCA)
Primary Biliary Cirrhosis (PBC)
Our current clinical focus is on the development of OCA, a novel, orally administered, first-in-class FXR agonist that we believe has broad liver-protective properties and may effectively counter a variety of chronic insults to the liver that cause fibrosis, which can eventually lead to cirrhosis, liver transplant and death. Our first targeted disease is PBC, an orphan indication with a significant unmet medical need. Based on the potential protective effects of OCA in the liver, we are conducting clinical trials in additional patient populations and chronic liver disease indications with potentially significant market opportunities, with the view of expanding OCA’s therapeutic applications.
Investigators interested in consideration for possible clinical trial participation should complete a questionnaire at: http://intercept.fluidsurveys.com.